Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DT678 vs clopidogrel in NSTE-ACS patients undergoing PCI
CTR20241982Phase 2Terminated
- Sponsor
- Beijing SL Pharmaceutical
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of DT678 in non–ST-segment elevation acute coronary syndrome (NSTE-ACS), unstable angina, Non-ST-segment elevation myocardial infarction (NSTEMI), atherosclerotic disease, ischemic stroke, sponsored by Beijing SL Pharmaceutical. Started Jun 2024; status: terminated.
02
Drugs
DT678
03
Conditions
non–ST-segment elevation acute coronary syndrome (NSTE-ACS)unstable anginaNon-ST-segment elevation myocardial infarction (NSTEMI)atherosclerotic diseaseischemic stroke
Beyond the preview
Go deeper on CTR20241982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241982.